Amneal Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Amneal Pharmaceuticals (AMRX) Misses Q1 EPS by 1c; Offers FY22 Guidance
May 4, 2022 6:03 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.12, $0.01 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $498 million versus the consensus estimate of $503.97 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2022 EPS of $0.80-$0.85, versus the consensus of $0.84. Amneal... More
